The Future of the Microbiome Summit lasts three days and covers all sorts of brilliant & cutting-edge topics on the microbiome. Preliminary schedule is below. Keep an eye on this page for more updates soon!

DAY 1: Tuesday, March 23, 2021 Microbiome through life: Exploring new science and commercial strategies from the first 1,000 days to healthy aging

Day one of the Future of the Microbiome Summit will dive in to the most established areas of microbiome research and look at the latest applied science in these fields including:

Gut microbiome pattern reflects healthy aging and predicts survival in humans
Nathan Price,
Institute for Systems Biology & Onegevity Health

Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Francesco Asnicar, University of Trento

Focus on the first 1,000 days:
a) Rapid MinION profiling of preterm microbiota and antimicrobial-resistant pathogens
Lindsay Hall, Quadram Institute and the Technical University of Munich

b) Metagenomic insights of the infant microbiome community structure and function across multiple sites in the United States
David Kyle, Evolve BioSystems, Inc.

DAY 2: Wednesday, March 24, 2021 New opportunities and developing ideas in the science and business of the microbiome

Day two of the Future of the Microbiome Summit will explore the emerging big opportunities in microbiome science including:

The microbiome-gut-brain axis in acute and chronic brain diseases
Paul Wilmes, Luxembourg Centre for Systems Biomedicine

Personalization strategies: Beyond microbiome testing
Mariette Abrahams, Qina

Building tomorrow’s microbiome products: the contract manufacturer/ brand relationship
Underwritten by Health Wright Products
DAY 3: Thursday, March 25, 2021 Future perspectives: Innovation, Investment, and commercialization - from bugs to drugs

Day three of the Future of the Microbiome Summit will look at the latest emerging technologies and the future of pre-, pro-, post- biotics and live biotherapeutics.

Microbiome-Drug interactions: New opportunities for microbiome science
Fransisco Guarner, University Hospital Vall d’Hebron

Future of Live Biotherapeutics
Georges Rawadi, YSOPIA Bioscience and Joseph Simmons, Pharmabiotic Research Institute

Investment and innovation: From science to commercialization
Kara Bortone, Johnson & Johnson Innovation, JLABS and Jonathan Schieman, FitBiomics